Experience the use of phytopreparations Cyclodynon® in patients with insufficiency of corpus luteum and hyperprolactinemia


  • В. П. Сметник Scientific Center for Obstetrics, Gynecology and Perinatology, RAM S, Moscow, Russian Federation
  • Л. Б. Бутарева Gynecology and Perinatology, RAM S, Moscow, Russian Federation




corpus luteum insufficiency, hyperprolactinemia, prolactin, estradiol, progesterone, agnucaston, Cyclodynon®


Complex clinical and laboratory examination among 20 patients aged 25 to 41 years with relative hyperprolactinemia suffering from menstrual irregularities of various kinds was performed. The control group consisted of 15 healthy women. In patients with corpus luteum insufficiency, caused by hyperprolactinemia, in order to correct existing disorders phytopreparation agnucaston (Cyclodynon®) was used.

The results showed that agnucaston (Cyclodynon®) effectively reduced the increased secretion of prolactin, the drug increases cyclic secretion of progesterone in the luteal phase of the cycle, which helps normalize the menstrual rhythm.

The authors concluded that agnucaston (Cyclodynon®) can be considered an alternative to treatment with other stimulators of dopamine receptors in their intolerance in patients with hyperprolactinemia of non-tumor genesis.

Author Biographies

В. П. Сметник, Scientific Center for Obstetrics, Gynecology and Perinatology, RAM S, Moscow

MD, professor, head of the Gynecological Endocrinology Department

Л. Б. Бутарева, Gynecology and Perinatology, RAM S, Moscow

PhD, Gynecological Endocrinology Department, Scientific Center for Obstetrics


  1. Borisova, Y.F. About the sexual development of the Moscow school: Author's thesis for the degree of candidate of medical sciences. Moscow (1965).
  2. Wisniewskiy, A.S., Safronnikova, N.R., Melnikova, N.Y., Grigorieva, T.A. “New approaches to the syndrome of hyperprolactinemia.” Journal of Obstetrics and Gynecological Diseases, Vol. XL1X (Issue 1) (2000): 39–41.
  3. Zaks, L. Statistical estimation. Moscow. Statistics (1976).
  4. Kettayl, V.M., Arky, R.A. Pathophysiology of the endocrine system. SPb. Nevsky Dialect (2001): 28–40.
  5. Melnichenko, G.A., Serebryanskyi, O.J., Romentsova, T.N. “Norprolac – a new dopamine agonist.” Medicine for everyone, 2 (Vol.1) (1997): 22–24.
  6. Nazarenko, T.A., Durinyan, E.R., Chechurova, T.N. “Health of women with ovulation disorders.” Problems of reproduction, 2 (Vol. 5) (1999): 48–51.
  7. Ovsyannikova, T.V. “Hyperprolactinemia.” Medicine for everyone, 2 (Vol. 1) (1997): 9–21.
  8. Ovsyannikova, T.V. “The pathogenesis, clinical manifestations, diagnostics and long-term results of treatment of infertility in hyperprolactinemia in women: Author's thesis for the degree of doctor of medical sciences.” Moscow (1990).
  9. Platonov, A.E. Statistical analysis in medicine and biology: the problem, terminology, logic, computer methods. Moscow. RAM S (2000).
  10. Prilepskaya, V.N. “Secondary amenorrhea.” Obstetrics and Gynecology, 12 (1990): 61–67.
  11. Smetnik, V.P. “Hyperprolactinemia and dysfunction of the reproductive system.” Obstetrics and Gynecology, 4(1990): 75–79.
  12. Smetnik, V.P., Marchenko, L.A., Osipova, A.A. “Cabergoline efficacy in the treatment of hyperprolactinemia.” Problems of reproduction, 3(2000): 42–47.
  13. Smetnik, V.P., Tumilovich, L.G. Non-immediate gynecology. Moscow. MIA (2003).
  14. Smetnik, V.P., Tumilovich, L.G. Non-immediate gynecology: guidelines. Moscow (1994).
  15. Phytohormones. Clinical lecture. Ed. by Radzinskiy, V.E., Kostin, I.N. Part 1 (2003).
  16. A sa, S., Kovacs, К., Stefaneanu, L., et al. “Pituitary adenomas in mice transgenic for growth hormone releasing-hormone.” Endocrinology, 131(1992): 2083–2089.
  17. Berger, D. Vitex Agnus castus: Unbedenklichkeit and Wirksamkeit beim praemenstruellen Syndrom, Wirkprinzipien und Wirkmechanismen eines neuetwickelten. Extraktes: Dissertation. — Univеrsitat Basel (1998).
  18. Hoberg, E., Sticher, O., Orjala, J.E., Meier, B. “Diterpene aus Agni-casti fructus und ihre Analytik.” Ztschr Phytother, 149(1999): 3.
  19. Jarr, H., Leonhardt, S., Wuttke, W., et al. “Agnus castus als dopaminerges Wirkprinzip in Mastodynon.” N Ztschr Phytother, 12(1991): 77–82.
  20. Luciano, A. “Clinical presentation of Hyperprolactinemia.” J Reprod Med, 44(1999): 1085–1090.
  21. MP H Edition Extrait de Psychiatric Practique de Medlien, 39(1987).
  22. N unes, M., Sobrinho, L., Calhaz-Jorge, C., et al. “Psychosomatic factors in patients with hyperprolactinemia and/or galactorrhea.” Obstet Gynecol, 55(1980): 591–595.
  23. R ao, G.M., Ney, E., Herbert, R.A. “Influence of diet on mammary cancer in transgenic mice bearing on oncogene expressed in mammar tissue.” Breast Cancer Res, 45(1997): 149–158.
  24. Sliulz, G., Speiser, P., Schultz, A.M., et al. “Agnus-castus extracts inhibit prolactin secretion of rat pituitary cells.” Horm Metabol Res, 25(1993): 243–255.
  25. Spengler, В., Schmidt, J., Porzel, A., Christoffel, V. Isolation and characterization of cyclic diterpenes from BNO 1095 (Vitex agnus castus). (1999).
  26. T an, S. Curr Opin Obstet Gyn, 2(1990): 378–385.
  27. W uttke, W., Gorkow, C, Jarry, H. “Dopaminergic compounds in Vitex agnes castus.” // D. Loew, N. Rietbrock (Hrsg). Phytopharmaka in forschung und klinischer Anwendung. Darmstadt. Steinkopff (1995): 81–91.
  28. Yen, S., Jaffe, R. Prolactin in human reproduction. Reproductive Endocrinology. Physiology. Pathophysiology. Clinical Management. 4 ed (1999): 257–283.



How to Cite

Сметник, В. П., & Бутарева, Л. Б. (2015). Experience the use of phytopreparations Cyclodynon® in patients with insufficiency of corpus luteum and hyperprolactinemia. REPRODUCTIVE ENDOCRINOLOGY, (23), 42–46. https://doi.org/10.18370/2309-4117.2015.23.42-46